ASLAN Pharmaceuticals Lim... (ASLN)
NASDAQ: ASLN
· Real-Time Price · USD
0.60
-0.10 (-14.27%)
At close: Jul 18, 2024, 10:00 PM
ASLAN Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 12M | 12M | 12M | 12M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 12M | 12M | 12M | 12M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -34.92M | -43.74M | -44.28M | -44.16M | -54.09M | -47.88M | -45.63M | -43.36M | -38.89M | -33.86M | -28.63M | -24.14M | -19.99M |
Interest Income | 82.17K | 404.98K | 618.89K | 704.12K | 676.58K | 354.46K | 130.48K | 43.86K | 2.51K | 219.00 | 331.00 | 533.00 | 627.00 |
Pretax Income | -34.9M | -44.09M | -45.02M | -46.24M | -57.45M | -51.28M | -46.02M | -43.66M | -36.08M | -30.11M | -26.65M | -21.79M | -20.43M |
Net Income | -35.03M | -44.22M | -45.19M | -46.41M | -57.42M | -51.2M | -45.86M | -43.48M | -36.02M | -29.84M | -26.42M | -21.13M | -19.66M |
Selling & General & Admin | 12.59M | 13.24M | 12.7M | 11.84M | 11.39M | 9.88M | 9.35M | 9.8M | 11.26M | 11.83M | 12.7M | 11.31M | 9.31M |
Research & Development | 34.33M | 42.5M | 43.58M | 44.31M | 42.7M | 38M | 36.28M | 33.57M | 27.63M | 22.02M | 15.94M | 12.86M | 10.71M |
Other Expenses | 36.03K | n/a | n/a | n/a | -126.56K | -126.56K | -126.56K | -126.56K | -21.39K | -21.39K | -21.39K | -131.63K | -110.23K |
Operating Expenses | 46.92M | 55.74M | 56.28M | 56.16M | 53.97M | 47.76M | 45.5M | 43.23M | 38.87M | 33.83M | 28.61M | 24.04M | 19.91M |
Interest Expense | 3.92M | 4.33M | 4.11M | 3.92M | 3.67M | 3.68M | 3.65M | 3.21M | 2.53M | 1.86M | 1.44M | 1.18M | 1.32M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 46.92M | 55.74M | 56.28M | 56.16M | 53.97M | 47.76M | 45.5M | 43.23M | 38.87M | 33.83M | 28.61M | 24.04M | 19.91M |
Income Tax Expense | 126.07K | 132.67K | 172.13K | 163.97K | -37.06K | -83.53K | -162.91K | -262.85K | -139.27K | 62.27K | 293.12K | 207.53K | 161.12K |
Shares Outstanding (Basic) | 746.82K | 691.32K | 688.09K | 657.72K | 593.13K | 557.96K | 557.96K | 557.96K | 557.96K | 553.52K | 557.31K | 556.94K | 411.46K |
Shares Outstanding (Diluted) | 746.82K | 691.32K | 688.09K | 657.72K | 593.13K | 557.96K | 557.96K | 557.96K | 557.96K | 556.85K | 557.31K | 557.31K | 411.46K |
EPS (Basic) | -49.5 | -68.5 | -75 | -80.5 | -100.75 | -91.5 | -82 | -77.75 | -64.5 | -57.75 | -59.25 | -54.75 | -58 |
EPS (Diluted) | -49.5 | -68.5 | -75 | -80.5 | -100.75 | -91.5 | -82 | -77.75 | -64.5 | -57.75 | -59.25 | -54.75 | -58 |
EBITDA | -30.98M | -39.76M | -40.9M | -42.33M | -53.78M | -47.61M | -44.68M | -42.77M | -35.83M | -30.54M | -25.19M | -20.24M | -16.45M |
EBIT | -30.99M | -39.76M | -40.91M | -42.33M | -53.78M | -47.61M | -42.18M | -40.27M | -33.36M | -28.06M | -25.38M | -20.82M | -19.32M |
Depreciation & Amortization | 3.62M | 3.65M | 3.38M | 1.83M | 307.38K | 274.98K | 942.96K | 594.76K | 3.06M | 3.32M | 2.95M | 3.05M | 2.63M |